PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION

The Lancet

Volumn 330, Issue 8549, 1987, Pages 3-9

  Hamsten, Anders ^a,b   Walldius, Göran ^a   Szamosi, Alfred ^a   Blombäck, Margareta ^a,b   Faire, UlfDe ^d   Dahlén, Gösta ^c   Landou, Christian ^a   Wiman, Björn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d King Gustaf V Research Institute Karolinska Hospital Karolinska Iristitutet Stockholm Sweden ^*

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGE; ANGIOGRAPHY; DIAGNOSIS; HEART; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR;

ADULT; FIBRINOGEN; FOLLOW-UP STUDIES; GLYCOPROTEINS; HEMOSTASIS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METHODS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; PROSPECTIVE STUDIES; RECURRENCE; RISK; TRIGLYCERIDES;

EID: 0023185776     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(87)93050-9     Document Type: Article

References (40)

1. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
2. Nomenclature and criteria for diagnosis of ischemic heart disease report of the Joint International Society and Federation of Cardiology/World Health Organisation Task Force on Standardization of Clinical Nomenclature
3. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction
4. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction
5. Lipoprotein fractionation
6. 3, without contamination of Lp(a), in human plasma
7. Electrophoretic separation of plasma lipoproteins in agarose gel
8. Classification of hyperlipidaemias and hyperlipoproteinaemias
9. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
10. On the intravenous glucose tolerance test
11. Insulin release insulin sensitivity and glucose intolerance
12. Non-ketotic diabetes mellitus: insulin deficiency or insulin resistance?
13. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus
14. Haemostatic function in myocardial infarction
15. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test)
16. Studies of Factor VIII procoagulant activity in plasma and concentrates using a semiautomated thrombin generation assay
17. Quantitive estimation of proteins by electrophoresis in agarose gel containing antibodies
18. Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH)
19. Inmunochemical quantitation of antigens by single radial immunodiffusion
20. Evidence for-a rapid inhibitor to tissue plasminogen activator in plasma
21. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate
22. Simple chromogenic peptide substrate assays for determining prekallikrem, kallikrein inhibition and kallikrein "like" activity in human plasma
23. Fibrin plate method with reagents purified by affinity chromatography and its use for determination of fibrinolytic and other proteolytic activity in saliva, bile and plasma
24. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association
25. The use of biplane angiography for the measurement of left ventricular volume in man
26. Nonsurgical reperfusion in evolving myocardial infarction
27. Intravenous streptokinase in evolving acute myocardial infarction
28. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase
29. Fibrinogen as a nsk factor for stroke and myocardial infarction
30. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study
31. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
32. Long-term results of a prospective randomised trial of coronary artery bypass surgery in stable angina pectoris
33. Coronary Artery Surgery Study (CASS): a randomised trial of coronary artery bypass surgery: survival data
34. Exercise-induced ischemia in mildly symptomatic patients with coronary-artery disease and preserved left ventricular function. Identification of subgroups at risk of death during medical therapy
35. Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction
36. Prognostic value of exercise testing, coronary angiography and left ventriculography 6-8 weeks after myocardial infarction
37. Determinants of prognosis in survivors of myocardial infarction A prospective clinical angiographic study
38. Is there an indication for coronary angiography in patients under 60 years of age with no or minimal angina pectoris after a first myocardial infarction?
39. Use of radionuclide angiography and an electrocardiographic stress test to diagnose multiple vessel disease after a first episode of uncomplicated myocardial infarction